1. Specific allergy and asthma prevention coming to an age: A milestone in children 
Claus Bachert, MD, PhD, Cezmi A. Akdis, MD 
Journal of Allergy and Clinical Immunology 
Volume 141, Issue 2, Pages (February 2018)
DOI: /j.jaci
Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
Improved features of asthma and allergic rhinoconjunctivitis in the GAP trial: asthma symptoms (odds ratio [OR], 0543; P = .017); asthma medication use (OR, 0.337; P = .002); asthma symptoms and asthma medication use (OR, 0.278; P = .0004); asthma symptoms, asthma medication use, and FEV1 reversibility of 12% or greater (OR, 0.177; P = .013); asthma symptoms, inhaled corticosteroid (ICS) use, and FEV1 reversibility of 12% or greater (OR, 0.205; P = .028).
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions